Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study.
Daniel J. George
Research Funding - Millennium
Paul G. Corn
No relevant relationships to disclose
M. Dror Michaelson
Consultant or Advisory Role - Millennium (U)
Research Funding - Millennium
Hans J. Hammers
No relevant relationships to disclose
Joshi J. Alumkal
No relevant relationships to disclose
Charles J. Ryan
Honoraria - Millennium
Justine Yang Bruce
No relevant relationships to disclose
Susan Moran
Employment or Leadership Position - Millennium
Stock Ownership - Millennium
Shih-Yuan Lee
Employment or Leadership Position - Millennium
Peter Mortimer
Employment or Leadership Position - Takeda Global RD London
Maha Hussain
No relevant relationships to disclose